Observation On Clinical Effect Of Aldose Reductase Inhibitor In The Treatment Of Non-proliferative Type-2 Diabetic Retinopathy

Objective :To observe the clinical effect of aldose reductase inhibitor(epalrestat tablet)in the treatment of non-proliferative type-2 diabetic retinopathy(NPDR).Methods:According to the admission criteria and exclusion criteria,50 eligible patients with non-proliferative type-2 DR hospitalized in Endocrine Department of the Third Affiliated Hospital of Nanchang University from December 2018 to July 2019 were selected and divided into two groups randomly.25 patients were in the control group,who were given routine treatment to control blood glucose,blood pressure,blood lipid and improve blood circulation.25 patients were in the treatment group,who were given epalrestat tablets(50mg tid)for orally administration before meals on the basis of routine treatment to control blood glucose,blood pressure,blood lipid and improve blood circulation.The treatment lasted for 24 weeks.Before treatment(0 week)and after treatment(24 weeks),liver and kidney function,blood glucose,blood lipid,blood pressure and eyeground photography were examined respectively,and the data were analyzed statistically by IBM-SPSS25.0 software.The retinal changes in eyeground photography after treatment were compared between the two groups.Results:A total of 50 people were enrolled in this study,of whom 3 did not complete the examination according to the design of this study and quit,and 2 did not take medicine according to the design of this study and quit.The final number of people who completed the study was 45.The treatment group consisted of 22 patients,including 14 males and 8 females,with an average age of 57.05 ± 8.52 years and an average course of disease of 7.68 ± 5.08 years;The control group consisted of 23 patients,including 11 males and 12 females,with an average age of 61.48 ± 7.17 years and an average course of disease of 9.52 ± 4.68 years.There was no statistically significant difference in general data(gender,age,course of disease)between the twogroups(P>0.05).There was no statistically significant difference in fasting blood glucose,glycosylated hemoglobin,low-density lipoprotein and blood pressure between the two groups before treatment(P>0.05).There was no statistically significant difference in composition ratio of DR stages between the two groups(P>0.05).After treatment,there was still no statistically significant difference in the above general examination data between the two groups(P>0.05).After 24 weeks of treatment,the DR improvement rate in the treatment group was 63.6%,and that in the control group was 10.9%.There was statistically significant difference between the two groups(P<0.05).Conclusion:Aldose reductase inhibitor(epalrestat tablet)is effective in treating non-proliferative DR,and can be used for treating non-proliferative type-2 DR.